Ca.Di.Group S.r.l. is one of the fastest growing family-owned company in the nutritional and food supplement business in Italy.
The Company was founded in 1993 by a family with a long tradition of understanding health problems and a dedication towards prevention with the aim to develop top grade nutritional products to fit the needs of the consumers.

Today we want to continue to distinguish ourselves from other companies within the Italian Nutraceutical market by using the highest quality standards to achieve successful results.

Through our vision, continued research and development of innovative products in combination with good marketing strategies, Ca.Di.Group actively promote 12 innovative and patented quality products in Specialty Therapeutic Areas (Gastroenterologic, Dietologic, Pediatric, Dermatologic, Obstetric, Gynaecological, Radiotherapy and Colonproctological) with a well established and trained Sales Force across Italy.

The products, owned by Ca.Di.Group, are produced in specialized factories authorized by the Italian Ministry of Health.

The products are sold through the usual pharmaceutical channels (wholesalers, pharmacies). Special prices are offered to public and private hospitals.

In Italy sales are promoted by medical representatives (trained with scientific courses) who promote the products to specialist doctors and participate to the most important pharmaceutical congresses.

In Europe the products are distributed by Vivapharma for the Hungarian market and by Alba Medica for the Greek market.

In the near future Ca.Di.Group is planning to launch in the market new products which have the final composition and the production already defined, awaiting only to complete the clinical tests by some Italian Universities.

Ca.Di. Group was the first company to:

• use Inulin in oral solution to improve the hydratation and to normalize the intestinal microflora (Sodioral con inulina);
• introduce, distribute and sell peppermint oil in enteric coated capsules for the treatment of irritable bowel syndrome (Mintoil);
• produce chocolate that contains fiber, which make easier the fiber treatment especially with children and also providing an important antioxidant supplement (Cadicioc);
• demonstrate the effectiveness of the Glucomannan for decreasing total cholesterol and LDL cholesterol in children, without any adverse reaction (Ecamannan);
• demonstrate the effectiveness of synbiotic (Probinul) in the eradication of the H. Pylori treatment;
• demonstrate the effectiveness of synbiotic (Probinul) to reduce the flatulence of patients with IBS;
• demonstrate the efficacy and safety of the association of polimetossiflavons, polycosanols and chromium polynicotinate for hypercholesterolemic patients.
• Carry out pharmacological studies on the fibrosis treatment (colon and hepatic) based on new associations of nutraceuticals. The results are very good and we believe to introduce soon in the market a product that will be the only one against the onset and development of fibrosis.

Moreover some clinic studies are in progress in some important Italian oncologic hospitals to use a specific product (Faringel) in radiotherapy treatments (mucositis or esophageal inflammation).

It is important to underline that the clinical trials related to Ca.Di. Group products are published on very important international medical journals like BRITISH MEDICAL JOURNAL, AMERICAN JOURNAL OF GASTROENTEROLOGY, NUTRITION, METABOLISM AND CARDIOVASCULAR DISEASES.

All the Ca.Di.Group products are:

• Gluten free and listed in the Italian Celiac Association handbook
• Lactose free